2,4-diamino-5-bromomethylpyrimidine hydrobromide | 20781-09-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,4-diamino-5-bromomethylpyrimidine hydrobromide
• 英文别名: 5-(bromomethyl)pyrimidine-2,4-diamine hydrobromide；5-(bromomethyl)pyrimidine-2,4-diamine;hydrobromide
• CAS: 20781-09-3
• 化学式: BrH*C₅H₇BrN₄
• 分子量: 283.953
• InChiKey: HYBBIZVZKIGHTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.11
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2,4-diamino-5-bromomethylpyrimidine hydrobromide 在 水 、 copper(II) sulfate 、 sodium ascorbate 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.0h， 生成 1-cyclopropyl-7-(4-(((2,4-diaminopyrimidin-5-yl)methoxy)methyl)-1H-1,2,3-triazol-1-yl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  Structure aided design of chimeric antibiotics

  摘要：

  The rise of antibiotic resistance is of great clinical concern. One approach to reducing the development of resistance is to co-administer two or more antibiotics with different modes of action. However, it can be difficult to control the distribution and pharmacokinetics of two drugs to ensure both concentrations remain within the range of therapeutic efficacy whilst avoiding adverse effects. Hybrid drugs, where two drugs are linked together with a flexible linker, have been explored, but the resultant large, flexible molecules can have poor bioavailability. We have developed a chimeric approach using click chemistry where the pharmacophores of two drugs are overlapped into a single smaller, more drug-like molecule. Design and selection of compounds were assisted by in silico structural docking. We prepared a series of compounds that include candidates showing activity against the targets of both trimethoprim; dihydrofolate reductase, and ciprofloxacin; DNA gyrase and topoisomerase IV. The resultant triazole containing molecules show modest, but broad spectrum activities against drug sensitive and resistant Gram-negative and Gram-positive bacteria, with no observable cytotoxicity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.019
• 作为产物：
  描述：

  2,4-二氨基嘧啶-5-甲醛 在 sodium tetrahydroborate 、 氢溴酸 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 8.0h， 生成 2,4-diamino-5-bromomethylpyrimidine hydrobromide
  参考文献：
  名称：

  Structure aided design of chimeric antibiotics

  摘要：

  The rise of antibiotic resistance is of great clinical concern. One approach to reducing the development of resistance is to co-administer two or more antibiotics with different modes of action. However, it can be difficult to control the distribution and pharmacokinetics of two drugs to ensure both concentrations remain within the range of therapeutic efficacy whilst avoiding adverse effects. Hybrid drugs, where two drugs are linked together with a flexible linker, have been explored, but the resultant large, flexible molecules can have poor bioavailability. We have developed a chimeric approach using click chemistry where the pharmacophores of two drugs are overlapped into a single smaller, more drug-like molecule. Design and selection of compounds were assisted by in silico structural docking. We prepared a series of compounds that include candidates showing activity against the targets of both trimethoprim; dihydrofolate reductase, and ciprofloxacin; DNA gyrase and topoisomerase IV. The resultant triazole containing molecules show modest, but broad spectrum activities against drug sensitive and resistant Gram-negative and Gram-positive bacteria, with no observable cytotoxicity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.019

文献信息

• Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens
  作者：Seema Bag、Nilesh R. Tawari、Mariam S. Degani、Sherry F. Queener

  DOI：10.1016/j.bmc.2010.03.031

  日期：2010.5

  with design, synthesis and biological evaluation of novel, diverse compounds as potential inhibitors of dihydrofolate reductase (DHFR) from opportunistic microorganisms; Pneumocystis carinii (pc), Toxoplasma gondii (tg) and Mycobacterium avium (ma). A set of 14 structurally diverse compounds were designed with varying key pharmacophoric features of DHFR inhibitors, bulky distal substitutions and different

  目前的工作涉及新型，多样的化合物的设计，合成和生物学评估，这些化合物可作为机会微生物中二氢叶酸还原酶（DHFR）的潜在抑制剂。卡氏肺孢子虫（pc），弓形虫（tg）和鸟分枝 杆菌（嘛）。设计了一组14种结构多样的化合物，这些化合物具有DHFR抑制剂的关键药理学特征，远侧大体积取代以及连接远侧部分和2,4-二氨基嘧啶核的不同桥。合成了设计的化合物，并在酶分析中针对pc，tg和ma DHFR进行了评估。大鼠肝脏（rI）DHFR被用作哺乳动物标准品。作为该项目的下一个逻辑步骤，进行了灵活的分子对接研究，以预测这些化合物在pcDHFR活性位点的结合方式，并使用MM-GBSA协议对获得的对接位姿进行后处理，以预测相对结合亲和力。在大多数情况下，预测的结合模式能够使实验结果合理化。特别令人感兴趣的是，对接分数和MM-GBSA预测的ΔG结合能够区分活性化合物和低活性化合物。此外，在IC 50值和MM-GBSA预测的ΔG结合之间获得了0
• Pyrimidine compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US05688798A1

  公开（公告）日：1997-11-18

  Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each individually are lower-alkyl or amino, A is ##STR2## B is hydrogen in A.sup.4, A.sup.5 and A.sup.6 ; ##STR3## in A.sup.1 -A.sup.6 ; lower-alkoxy in A.sup.4 -A.sup.6 ; and lower-alkyl, styryl, phenylethynyl or benzoyloxy-lower-alkyl in A.sup.1 and A.sup.2 ; n is 0, 1 or 2; m, p are, independently 0, 1 and R.sup.3, R.sup.4, R.sup.5 and R.sup.6 each independently are hydrogen, halogen, lower-alkyl, trifluoromethyl, lower-alkoxy or nitro, and pharmaceutically acceptable acid addition salts thereof. These compounds are useful in the control or prevention of illnesses which are caused by disorders of the dopamine system, in particular psychotic illnesses such as schizophrenia.

  该公式化合物的化合物##STR1##其中R.sup.1和R.sup.2分别为较低的烷基或氨基，A为##STR2## B为A.sup.4中的氢，A.sup.5和A.sup.6；##STR3##在A.sup.1-A.sup.6中；A.sup.4-A.sup.6中的较低烷氧基；以及A.sup.1和A.sup.2中的较低烷基，苯乙烯基，苯乙炔基或苯甲酰氧基较低烷基；n为0、1或2；m、p分别为0、1，R.sup.3、R.sup.4、R.sup.5和R.sup.6各自独立为氢、卤素、较低烷基、三氟甲基、较低烷氧基或硝基，以及其药学上可接受的酸盐。这些化合物在控制或预防由多巴胺系统紊乱引起的疾病中特别有用，特别是精神分裂症等精神疾病。
• Novel Dihydrofolate Reductase Inhibitors. Structure-Based versus Diversity-Based Library Design and High-Throughput Synthesis and Screening
  作者：Pierre C. Wyss、Paul Gerber、Peter G. Hartman、Christian Hubschwerlen、Hans Locher、Hans-Peter Marty、Martin Stahl

  DOI：10.1021/jm020495y

  日期：2003.6.1

  design. Different classes of inhibitors of DHFR were identified in this way, including compounds derived from di-, tri-, and tetracyclic amines. In general, these products showed high activity against the enzymes derived from both TMP-sensitive and TMP-resistant Streptococcus pneumoniae. Some compounds possessed appreciable selectivity for the bacterial over the human enzyme, whereas other compounds were

  将在5-位带有N，N-二取代的氨基甲基残基的新型2，4-二氨基嘧啶设计为二氢叶酸还原酶（DHFR）抑制剂。这些化合物通过在室温下在极性溶剂中和在三乙胺存在下用仲胺处理1-[（2,4-二氨基-5-嘧啶基）甲基]溴化吡啶鎓而获得。发现该方法非常有效并且适用于高通量合成。此外，我们发现可以对粗制反应混合物进行酶促和体外抗菌活性的高通量筛选，从而避免了任何纯化步骤。根据结构和多样性相关的标准，选择了1200多种专有的仲胺用于高通量合成，然后将所得产物进行高通量筛选。通过基于结构的文库设计比通过基于多样性的文库设计获得了更多的命中数和明显更多的活性化合物。以此方式鉴定了不同种类的DHFR抑制剂，包括衍生自二，三和四环胺的化合物。通常，这些产品对源自TMP敏感和TMP耐药的肺炎链球菌的酶显示出高活性。一些化合物对细菌具有比人类酶明显的选择性，而其他化合物则完全没有选择性。在大多数情况下，活性酶抑制剂也
• Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
  申请人：Dana-Farber Cancer Institute

  公开号：US07056911B1

  公开（公告）日：2006-06-06

  The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention and particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection such as pneumocystis pneumonia, toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.

  本发明涉及药物活性化合物，以及利用或包含其中一种或多种这样的化合物的治疗方法和药物组合物。本发明的化合物特别适用于治疗或预防与寄生虫感染相关的疾病，如肺孢子菌肺炎、弓形虫病、隐孢子虫病、利什曼病和疟疾。
• Folate-Synthesizing Enzyme System as Target for Development of Inhibitors and Inhibitor Combinations against <i>Candida </i><i>a</i><i>lbicans</i>Synthesis and Biological Activity of New 2,4-Diaminopyrimidines and 4‘-Substituted 4-Aminodiphenyl Sulfones
  作者：Thomas Otzen、Ellen G. Wempe、Brigitte Kunz、Rainer Bartels、Gudrun Lehwark-Yvetot、Wolfram Hänsel、Klaus-Jürgen Schaper、Joachim K. Seydel

  DOI：10.1021/jm030931w

  日期：2004.1.1

  The paper describes the design, synthesis, and testing of inhibitors of folate-synthesizing enzymes and of whole cell cultures of Candida albicans. The target enzymes used were dihydropteroic acid synthase (SYN) and dihydrofolate reductase (DHFR). Several series of new 2,4-diaminopyrimidines were synthesized and tested as inhibitors of DHFR and compared with their activity against DHFR derived from mycobacteria and Escherichia coli. To test for selectivity, also rat DHFR was used. A series of substituted 4-aminodiphenyl sulfones was tested for inhibitory activity against SYN and the I-50 values compared to those obtained previously against Plasmodium berghei- and E. coli-derived SYN. Surprisingly, QSAR equations show very similar structural dependencies. To find an explanation for the large difference in the I-50 values observed for enzyme inhibition (SYN, DHFR) and for inhibition of cell cultures of Candida, mutant strains with overexpressed efflux pumps and strains in which such pumps are deleted were included in the study and the MICs compared. Efflux pumps were responsible for the low activity of some of the tested derivatives, others showed no increase in activity after pumps were knocked out. In this case it may be speculated that these derivatives are not able to enter the cells.